
    
      A staged pre-market, single-arm, clinical study designed to collect acute and long-term
      safety and efficacy data for the Adagio AF Cryoablation System (iCLASâ„¢). Patient population
      will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure.
      Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will
      receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment
      at one, three, six, and twelve months.
    
  